https://www.selleckchem.com/products/gne-781.html
O6methylguanine-DNA methyltransferase ( ) promoter methylation is a biomarker widely used to predict the sensitivity of -wildtype glioblastoma to temozolomide therapy. Given that the status has critical effects on the survival and epigenetic features of glioblastoma, we aimed to assess the role of promoter methylation in -mutant glioblastoma. This study included 187 -mutant glioblastomas and used 173 -wildtype glioblastomas for comparison. Kaplan-Meier curves and multivariate Cox regression were used to study the predictive effects. Com
Like
Comment
Share
